MyMD Pharmaceuticals presents data from MYMD-1 preclinical study

MyMD Pharmaceuticals is presenting data from a preclinical study of investigational, oral TNF-a inhibitor MYMD-1 at the 2023 Society of Toxicology Annual Meeting, or SOT, in Nashville. Study results comparing MYMD-1 to placebo were very highly significant and showed MYMD-1 reduced histopathological changes and the severity of standard arthritis clinical trial measures. The study was designed to investigate the anti-inflammatory effects of MYMD-1 in a rheumatoid arthritis model that mimics features of arthritis in humans and included commonly used clinical arthritis endpoints. Histopathology parameters were very highly significant vs placebo for composite score, bone resorption, periosteal/exostatic change, inflammation, pannus/synovial hyperplasia, and in life pawn volume. Disease severity was reduced by 47% with MYMD-1 at 450 mg/kg/day orally versus a 37% reduction for etanercept 10 mg/kg by subcutaneous injection. The research model was induced by an intravenous injection of a monoclonal antibodies cocktail that directed to collagen type II on Day 1, followed by an intraperitoneal injection of the endotoxin LPS on Day 6. Three doses of MYMD-1 were tested, and the dose formulations were administered by oral gavage, twice daily, starting at the onset of the disease. Etanercept and Dexamethasone were also administered respectively twice weekly by subcutaneous injection and daily by oral gavage as positive controls.